Current Neuro-Oncology
Volume
24 Number 9
15 May 2022
Home > Publications > Current Neuro-Oncology > Volume 24, Year 2022 > Number 9, 15 May
Scarpelli
DB, Jaboin JJ.
Exploring
the Role of Resection Post-Radiation
Therapy
in Gliomas.
Int
J Radiat Oncol Biol Phys. 2022 May 1;113(1):11∟.
doi: 10.1016/j.ijrobp.2021.03.013∟.
PMID: 35427542∟.
Case report. ˍ
Helis CA, Prim SN, Cramer CK,
Strowd R, Lesser GJ, White JJ, Tatter SB, Laxton AW, Whitlow C, Lo
HW, Debinski W, Ververs JD, Black PJ, Chan MD.
Clinical
outcomes of dose-escalated re-irradiation in patients with
recurrent high-grade glioma.
Neurooncol
Pract. 2022 May 2;9(5):390-401∟.
doi: 10.1093/nop/npac032∟.
PMID: 36134018∟.
Observational
study. ˍ
Lim
M, Weller M, Idbaih A, Steinbach J, Finocchiaro G, Raval RR,
Ansstas G, Baehring
J, Taylor JW, Honnorat J, Petrecca K, De Vos F, Wick A, Sumrall A,
Sahebjam
S, Mellinghoff IK, Kinoshita M, Roberts M, Slepetis R, Warad D,
Leung D,
Lee M, Reardon DA, Omuro A.
Phase
3 Trial of Chemoradiotherapy With
Temozolomide
Plus Nivolumab or Placebo for Newly Diagnosed Glioblastoma With
Methylated
MGMT Promoter.
Neuro
Oncol. 2022 May 2;24(11):1935-1949∟.
doi: 10.1093/neuonc/noac116∟.
PMID: 35511454∟.
Interventional
study.
ˍ
Kandregula
S, Konar S, Sadashiva N, Nagesh M, Kalahasti SR, Krishna U, Saini
J,
Shukla D, Santosh V.
Diffuse
intrinsic pontine gliomas in adults: A
retrospective
study.
Neurol
India. 2022 May 3;70(2):584-590∟.
doi: 10.4103/0028-3886.344673?
PMID:
35532623∟.
Observational study. ˍ
Ohno
M, Miyakita Y, Takahashi M, Yanagisawa S, Tamura Y, Kawauchi D,
Kikuchi M, Igaki H, Yoshida A, Satomi K, Matsushita Y, Ichimura K,
Narita Y.
Assessment
of
therapeutic outcome and role of reirradiation in patients with
radiation-induced glioma.
Radiat
Oncol. 2022 May 3;17(1):85∟.
doi: 10.1186/s13014-022-02054-x∟.
PMID: 35505351∟.
Observational study. ˍ
Alanio
C, Binder ZA, Chang RB, Nasrallah MP, Delman D, Li JH, Tang OY,
Zhang LY, Zhang JV, Wherry EJ, O'Rourke DM, Beatty
GL.
Immunological
features in de
novo
and recurrent glioblastoma associate with survival
outcomes.
Cancer
Immunol Res. 2022 May 4;10(7):800-810∟.
doi: 10.1158/2326-6066.CIR-21-1050∟.
PMID: 35507919∟.
Laboratory investigation˰ ˍ
Lin
MS, Lee CH, Chen SY, Shen CC.
Collision
brain tumor with atypical meningioma and glioblastoma: Case
report.
Int
J Surg Case Rep. 2022 May 4;94:107137∟.
doi: 10.1016/j.ijscr.2022.107137∟.
PMID: 35658305∟.
Case report. ˍ
König
D, Hench J, Frank S, Dima L, Bratic Hench I, Läubli
H.
Larotrectinib
Response
in NTRK3 Fusion-Driven Diffuse High-Grade Glioma.
Pharmacology.
2022 May
6;107(7-8):433-438∟.
doi: 10.1159/000524399∟.
PMID: 35526519∟.
Case
report. ˍ
*
Feldheim
J, Kessler AF, Feldheim JJ, Schulz E, Wend D, Lazaridis L,
Kleinschnitz
C, Glas M, Ernestus RI, Brandner S, Monoranu CM, Löhr M,
Hagemann C.
Effects
of Long-Term Temozolomide Treatment on Glioblastoma and
Astrocytoma WHO
Grade 4 Stem-like Cells.
Int
J Mol Sci. 2022 May 7;23(9):5238∟.
doi: 10.3390/ijms23095238∟.
PMID: 35563629∟.
Laboratory
investigation. ˍ
Seliger
C, Nürnberg C, Wick W, Wick A.
Lung
toxicity of lomustine in the treatment of progressive
gliomas.
Neurooncol
Adv. 2022 May 10;4(1):vdac068∟.
doi: 10.1093/noajnl/vdac068∟.
PMID: 35664555∟.
Observational study. ˍ
Simfukwe
K, Iakimov I, Sufianov R, Borba L, Mastronardi L, Shumadalova
A.
Application
of Intraoperative Ultrasound Navigation in Neurosurgery.
Front
Surg. 2022 May 10;9:900986∟.
doi: 10.3389/fsurg.2022.900986∟.
PMID: 35620193∟.
Observational study. ˍ
Bartlett
A, Lane A, Chaney B, Escorza NY, Black K, Cochrane A, Minturn J,
Bartels
U, Warren K, Hansford J, Ziegler D, Diez B, Goldman S, Packer R,
Kieran M,
DeWire-Schottmiller M, Erker C, Monje-Deisseroth M, Wagner L,
Koschmann C, Dorris
K, Shih CS, Hassall T, Samson Y, Fisher P, Wang SS, Tsui K,
Sevlever G, Zhu
X, Dexheimer P, Asher A, Fuller C, Drissi R, Jones B, Leach J,
Fouladi M.
Characteristics
of Children ≤36 Months of Age with Diffuse Intrinsic Pontine
Glioma
(DIPG): A Report from the International DIPG Registry.
Neuro
Oncol. 2022 May
12:noac123∟.
doi: 10.1093/neuonc/noac123∟.
PMID: 35552452∟.
Observational study˰ ˍ
Eisele
A, Seystahl K, Rushing EJ, Roth P, Le Rhun E, Weller M, Gramatzki
D.
Venous
thromboembolic events in glioblastoma patients: an epidemiological
study.
Eur
J Neurol. 2022 May 12∟.
doi: 10.1111/ene.15404∟.
PMID: 35545894∟.
Observational study. ˍ
Gerritsen
JKW, Zwarthoed RH, Kilgallon JL, Nawabi NL, Jessurun CAC, Versyck
G, Pruijn KP, Fisher FL, Larivière E, Solie L, Mekary RA,
Satoer DD, Schouten JW, Bos EM, Kloet A, Nandoe Tewarie R, Smith
TR, Dirven CMF, De Vleeschouwer S, Broekman MLD, Vincent
AJPE.
Effect
of awake craniotomy in glioblastoma in eloquent areas (GLIOMAP): a
propensity score-matched analysis of an international,
multicentre, cohort study.
Lancet
Oncol. 2022 May 12;23(6):802-817∟.
doi: 10.1016/S1470-2045(22)00213-3∟.
PMID: 35569489∟.
Observational study˰ ˍ
Martínez-García
M, Velasco G, Pineda E, Gil-Gil M, Alameda F, Capellades J,
Martín-Soberón MC, López-Valero I, Tovar
Ambel E, Foro P, Taus Á, Arumi M, Hernández-Laín
A, Sepúlveda-Sánchez JM.
Safety
and Efficacy of Crizotinib in Combination with Temozolomide and
Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase
Ib GEINO 1402 Trial.
Cancers
(Basel). 2022 May 12;14(10):2393∟.
doi: 10.3390/cancers14102393∟.
PMID: 35625997∟.
Interventional study. ˍ
Pinho
MP, Lepski GA, Rehder R, Chauca-Torres NE, Evangelista GCM,
Teixeira SF, Flatow EA, de Oliveira JV, Fogolin CS, Peres N,
Arévalo A, Alves V, Barbuto JAM, Bergami-Santos
PC.
Near-Complete
Remission of Glioblastoma in a Patient Treated with an Allogenic
Dendritic Cell-Based Vaccine: The Role of Tumor-Specific
CD4+T-Cell Cytokine Secretion Pattern in Predicting Response and
Recurrence.
Int
J Mol Sci. 2022 May 12;23(10):5396∟.
doi: 10.3390/ijms23105396∟.
PMID: 35628206∟.
Case report. ˍ
Reed-Guy
L, Desai AS, Phillips RE, Croteau D, Albright K, O'Neill M, Brem
S, O'Rourke
DM, Amankulor NM, Bagley SJ.
Risk
of intracranial hemorrhage with
direct
oral anticoagulants versus low molecular weight heparin in
glioblastoma: A
retrospective cohort study.
Neuro
Oncol. 2022 May 12, 2022:noac125∟.
doi: 10.1093/neuonc/noac125∟.
PMID: 35551405∟.
Observational study˰ ˍ
*
Caccese
M, Simonelli M, Villani V, Rizzato S, Ius T, Pasqualetti F, Russo
M, Rudà R, Amoroso R, Bellu L, Bertorelle R, Cavallin F,
Dipasquale A, Carosi M, Pizzolitto S, Cesselli D, Persico P,
Casini B, Fassan M, Zagonel V, Lombardi G.
Definition
of the Prognostic Role of MGMT Promoter Methylation Value by
Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma
Patients Treated with Radiochemotherapy: A Large Multicenter
Study.
Cancers
(Basel). 2022 May 13;14(10):2425∟.
doi: 10.3390/cancers14102425∟.
PMID: 35626029∟.
Observational study. ˍ
Telang
S, Chang S.
Targeting
Resistance in Medulloblastoma.
FASEB
J. 2022
May
13;36
Suppl 1∟.
doi: 10.1096/fasebj.2022.36.S1.R5885∟.
PMID: 35555839? Laboratory investigation, Meeting abstract˰
ˍ
Niehusmann
P, Stensvold E, Leske H, Pietsch T, Goschzik T, Gielen GH,
Due-Tønnessen B, Frič R, Nilssen Y, Brandal
P.
Molecular
pathological insights reveal a high number of unfavorable risk
patients among children treated for medulloblastoma and CNS-PNET
in Oslo 2005-2017.
Pediatr
Blood Cancer. 2022 May 15, 2022:e29736∟.
doi: 10.1002/pbc.29736∟.
PMID: 35570402∟.
Observational study. ˍ